Article
Patient compliance improves with twice-daily dosing
Fort Lauderdale, FL-A twice-daily dosing regimen of pemirolast potassium 0.1% ophthalmic solution (Alamast, Santen Inc., of Napa, CA, and Tampere, Finland) is as effective as the four-times-daily regimen of the drug for treating seasonal allergic conjunctivitis. The simpler dosing regimen may enhance patient compliance.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Part 6: Biggest innovations in ophthalmology in 50 years
Part 5: Biggest innovations in ophthalmology in 50 years
Part 4: Biggest innovations in ophthalmology in 50 years
NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
Part 3: Biggest innovations in ophthalmology in 50 years
Setting the stage in LA: Neda Shamie, MD, on the 19th Annual Controversies in Modern Eye Care
Part 2: Biggest innovations in ophthalmology in 50 years
Part 1: Biggest innovations in ophthalmology in 50 years
World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Related Content
